Table 1. Patient characteristics of the tissue microarray cohort.
| Primary Site | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Oral Cavity (23%) | Oropharynx (31%) | Hypopharynx (12%) | Larynx (33%) | Total Cohort (100%) | |||||||
| Count | % | Count | % | Count | % | Count | % | Count | % | ||
| T | 1 | 50 | 38,8% | 32 | 18,3% | 7 | 10,6% | 80 | 44,0% | 169 | 30,6% |
| 2 | 52 | 40,3% | 59 | 33,7% | 20 | 30,3% | 41 | 22,5% | 172 | 31,2% | |
| 3 | 13 | 10,1% | 54 | 30,9% | 13 | 19,7% | 38 | 20,9% | 118 | 21,4% | |
| 4 | 11 | 8,5% | 30 | 17,1% | 25 | 37,9% | 23 | 12,6% | 89 | 16,1% | |
| missing | 3 | 2,3% | 0 | 0,0% | 1 | 1,5% | 0 | 0,0% | 4 | 0,7% | |
| total | 129 | 100,0% | 175 | 100,0% | 66 | 100,0% | 182 | 100,0% | 552 | 100,0% | |
| N | 0 | 74 | 57,4% | 41 | 23,4% | 14 | 21,2% | 140 | 76,9% | 269 | 48,7% |
| 1 | 22 | 17,1% | 34 | 19,4% | 14 | 21,2% | 8 | 4,4% | 78 | 14,1% | |
| 2a | 5 | 3,9% | 10 | 5,7% | 6 | 9,1% | 6 | 3,3% | 27 | 4,9% | |
| 2b | 20 | 15,5% | 50 | 28,6% | 19 | 28,8% | 15 | 8,2% | 104 | 18,8% | |
| 2c | 4 | 3,1% | 29 | 16,6% | 8 | 12,1% | 10 | 5,5% | 51 | 9,2% | |
| 3 | 0 | 0,0% | 8 | 4,6% | 2 | 3,0% | 1 | 0,5% | 11 | 2,0% | |
| missing | 4 | 3,1% | 3 | 1,7% | 3 | 4,5% | 2 | 1,1% | 12 | 2,2% | |
| total | 129 | 100% | 175 | 100% | 66 | 100% | 182 | 100% | 552 | 100% | |
| M | 0 | 125 | 96,9% | 167 | 95,4% | 64 | 97,0% | 173 | 95,1% | 529 | 95,8% |
| 1 | 3 | 2,3% | 7 | 4,0% | 2 | 3,0% | 9 | 4,9% | 21 | 3,8% | |
| missing | 1 | 0,8% | 1 | 0,6% | 0 | 0,0% | 0 | 0,0% | 2 | 0,4% | |
| total | 129 | 100% | 175 | 100% | 66 | 100% | 182 | 100% | 552 | 100% | |
| Grading | 1 | 11 | 9% | 3 | 2% | 0 | 0% | 6 | 3% | 20 | 4% |
| 2 | 72 | 56% | 99 | 57% | 25 | 38% | 95 | 52% | 291 | 53% | |
| 3 | 26 | 20% | 45 | 26% | 28 | 42% | 33 | 18% | 132 | 24% | |
| missing | 20 | 16% | 28 | 16% | 13 | 20% | 48 | 26% | 109 | 20% | |
| total | 129 | 100% | 175 | 100% | 66 | 100% | 182 | 100% | 552 | 100% | |
| HPV status (DNA) | HPV DNA negative | 123 | 96,1% | 149 | 87,1% | 63 | 95,5% | 178 | 97,8% | 513 | 93,0% |
| HPV DNA positive | 6 | 4,7% | 26 | 15,2% | 3 | 4,5% | 4 | 2,2% | 39 | 7,0% | |
| total | 129 | 100,8% | 175 | 102,3% | 66 | 100,0% | 182 | 100,0% | 552 | 100,9% | |
| HPV status (DNA + p16) | HPV negative | 123 | 96,1% | 151 | 88,3% | 64 | 97,0% | 182 | 100,0% | 520 | 95,1% |
| HPV positive | 5 | 3,9% | 20 | 11,7% | 2 | 3,0% | 0 | 0,0% | 27 | 4,9% | |
| missing | 1 | 0,8% | 4 | 2,3% | 0 | 0,0% | 0 | 0,0% | 5 | 0,9% | |
| total | 128 | 100,0% | 171 | 100,0% | 66 | 100,0% | 182 | 100,0% | 547 | 100,0% | |
| treatment approach | surgical | 116 | 89,9% | 137 | 78,3% | 54 | 81,8% | 151 | 83,0% | 458 | 83,0% |
| non-surgical | 1 | 0,8% | 32 | 18,3% | 11 | 16,7% | 30 | 16,5% | 74 | 13,4% | |
| other (non-curative) | 12 | 9,3% | 6 | 3,4% | 1 | 1,5% | 1 | 0,5% | 20 | 3,6% | |
| total | 129 | 100,0% | 175 | 100,0% | 66 | 100,0% | 182 | 100,0% | 552 | 100,0% | |
| sex | male | 75 | 58,1% | 132 | 23,3% | 56 | 9,7% | 154 | 27,6% | 417 | 75,5% |
| female | 54 | 41,9% | 43 | 7,8% | 10 | 1,8% | 28 | 5,1% | 135 | 24,5% | |
| total | 129 | 100,0% | 175 | 100,0% | 66 | 100,0% | 182 | 100,0% | 552 | 100,0% | |
| smoking_><median (36) | never smoker | 12 | 9,3% | 22 | 12,6% | 4 | 6,1% | 11 | 6,0% | 49 | 8,9% |
| <36 py | 24 | 18,6% | 53 | 30,3% | 25 | 37,9% | 65 | 35,7% | 167 | 30,3% | |
| >=36py | 36 | 27,9% | 73 | 41,7% | 27 | 40,9% | 81 | 44,5% | 217 | 39,3% | |
| missing | 57 | 44,2% | 27 | 15,4% | 10 | 15,2% | 25 | 13,7% | 119 | 21,6% | |
| total | 129 | 100,0% | 175 | 100,0% | 66 | 100,0% | 182 | 100,0% | 552 | 100,0% | |